The potential of erythropoietin and related strategies to stimulate erythropoiesis

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1081-1085

  Eckardt, K U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anemia; Cancer; Erythropoietin; Renal failure

Indexed keywords

ANTIGESTAGEN; DARBEPOIETIN ALFA; ERYTHROPOIETIN RECEPTOR; GENE ACTIVATED ERYTHROPOIETIN; HEMOGLOBIN; IRON; JANUS KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANEMIA; BRAIN INJURY; CANCER; CANCER CHEMOTHERAPY; CHRONIC INFLAMMATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; ERYTHROPOIESIS; GENE THERAPY; HUMAN; IRON THERAPY; NEUROPROTECTION; POSTOPERATIVE HEMORRHAGE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SUPPLEMENTATION; SURVIVAL; TREATMENT OUTCOME;

ANEMIA; ANIMALS; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GENE THERAPY; HUMANS; MOLECULAR MIMICRY; STIMULATION, CHEMICAL;

EID: 0034892051     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Pathophysiology of renal anemia
2. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology
3. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure
4. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
5. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients
6. Normalizing hematocrit in dialysis patients improves brain function
7. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)
8. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities
9. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients
10. Hematocrit level and associated mortality in hemodialysis patients
11. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
12. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
13. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin
14. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
15. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients
16. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
17. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
18. The effect of correctional mild anemia in severe resistant heart failure using subcutaneous erythroporetin and intravenous iron - A randomized controlled study
19. European best practice guidelines for the management of anaemia in patients with chronic renal failure
20. K/DOQI clinical practice guidelines for anemia of chronic kidney disease
21. European survey of anemia management - European best practice guidelines 9-13: Anemia management
22. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin
23. Erythropoietin and anemia of cancer
24. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer
25. Anemia, hypoxia and transfusion in patients with cervix cancer: A review
26. Clinical benefit from erythropoietin
27. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models
28. Pathogenesis and treatment of the anemia of chronic disease
29. Advances in the anemia of chronic disease
30. Consensus statement: Anemia in HIV infection - Current trends, treatment options, and practice strategies. Anemia in HIV Working Group
31. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease
32. Anemia in IBD: The overlooked villain
33. Transfusion medicine - Second of two parts: Blood conservation
34. Erythropoietin to minimize perioperative blood transfusion: A systemic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators
35. Cost-effectiveness of epoetin and autologous blood donation in reducing allogeneic blood transfusions in coronary artery bypass graft surgery
36. Important role of non-diagnostic blood loss and diminished erythropoietic response in the anemia of medical intensive care patients
37. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized double blind placebo controlled trial
38. Organ distribution of erythropoietin messenger RNA in normal and uremic rats
39. Erythropoietin gene expression in human, monkey and murine brain
40. Erythropoietin is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death
41. In vivo evidence that erythropoietin protects neurons from ischemic damage
42. A potential role for erythropoietin in focal permanent cerebral ischemia in mice
43. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
44. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
45. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: Results from a randomized controlled multicentre trial. Swedish Study Group
46. The structure, organization, activation and plasticity of the erythropoietin receptor
47. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å
48. Mimicry of erythropoietin by a nonpeptide molecule
49. Erythropoietin mimetic peptides and the future
50. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals
51. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis
52. 2 homeostasis by hypoxia-inducible factor 1
53. Epolones: Novel sesquiterpene-tropolones from fungus OS-F69284 that induce erythropoietin in human cells
54. Epolones induce erythropoietin expression via hypoxia-inducible factor-1 alpha activation
55. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure
56. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector
57. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension
58. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
59. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system
60. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector